- Bruker acquires minority stake in NovAliX in strategic move
- NovAliX and Bruker partnership is expression of synergies between a premium drug discovery CRO and high-value life-science instrument maker
- Aim is to enhance drug discovery and development success
- Bruker joins NovAliX and the Max Planck Institute as founding partner of IBRB, a new institute and infrastructure offering access to biophysics instrumentation and drug discovery expertise
- NovAliX will establish scientific and technology platform to expand its footprint in the US
Strasbourg, France – August 7, 2024 – NovAliX, a Contract Research Organization (CRO) specializing in drug discovery, has formed a strategic partnership with Bruker, a leader in scientific instruments, under which Bruker has taken a minority ownership stake in NovAliX. The strategic investment underscores the increasingly vital role being played by CROs in global drug discovery and research.
The investment by Bruker aims to leverage NovAliX’s expertise in structural biology, biophysics, and pharmacology to develop innovative high-end analytical solutions and services that increase the odds of success at each stage of drug development.
As bringing new drugs to market has become more difficult and expensive, Contract Research Organizations such as NovAliX have emerged as vital players in the industry by providing the expertise, flexibility, and efficiency required for early stage pharmaceutical research. The Novalix-Bruker partnership will enable both companies to accelerate the incubation, deployment, and support for advanced biophysical methods, based on Bruker’s leading analytical competencies and NovAliX’s expert services and innovation alliances.
Stephan Jenn, President of NovAliX, said:
Bruker is at the forefront of technology serving the life sciences and focuses on the best ways to deploy technology for the advancement of science. For over 20 years, NovAliX has independently developed an unrivaled research engine, combining our biophysics legacy with the therapeutic expertise of researchers from Janssen, Sanofi, and Galapagos, some of whom have won awards for discovering new drugs. Now, our alliance with Bruker marks a crucial step in further enhancing the research capacity we offer for our biopharmaceutical customers’ therapeutic projects.”
A key component of this partnership is the establishment of the Biophysics Institute for Biomedical Research (IBRB). This unique setting, involving a top-rated academic institution like the Max Planck Institute, a leading instrument provider like Bruker, and the scientific team from NovAliX, will support scientists in residence and visiting scientists from the biopharmaceutical industry seeking support for discovery and development projects.
Falko Busse, President of Bruker BioSpin, further explained: “We recognized NovAliX as a leading drug discovery CRO with an unrivaled technological and biophysical focus, thus presenting an opportunity to establish a strategic alliance with Bruker. Additionally, we were convinced by the IBRB concept as a novel approach to ensuring progress and access to the characterization technologies essential for the successful research and development of new therapies.”
The IBRB will bring together an instrument provider along with industry and academic scientists, to foster opportunities to develop next-generation technologies and methods for the benefit of therapeutic discoveries. This unique combination of state-of-the-art biophysics instruments and expertise in drug discovery will generate experimental data crucial for the success of drug discovery programs.
Denis Zeyer, CEO of NovAliX, emphasized the transformative potential of IBRB:
IBRB will significantly contribute to the ongoing transformation of this industry. By fostering interaction between stakeholders and organizing access to shared knowledge through the joint use of major facilities, IBRB will enable new therapeutic innovation to mature effectively.”
This new alliance between a technology leader in scientific instruments and a premier drug discovery CRO marks a significant step forward in therapeutic innovation. Historically dominated by pharmaceutical groups and biotech companies, this collaboration heralds the emergence of a new model capable of bringing therapeutic innovations to fruition and improving the success of current biopharma discovery and development projects.
About NovAliX
NovAliX is a fully integrated drug discovery CRO supporting therapeutic programs from target identification to the delivery of preclinical candidates. NovAliX enables successful discovery programs through an award-winning team of medicinal chemistry and pharmacology scientists, and a variety of screening and characterization technologies, including an outstanding DNA-encoded library platform and a comprehensive portfolio of biophysical techniques, including an in-house cryo-EM facility. NovAliX’s presence in therapeutic areas now spans oncology, inflammation, fibrosis, and infectious and kidney diseases.
For additional information, follow us on LinkedIn and Twitter.
Financial details were not disclosed.
Find below the full PR in English:
